Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Ramos

Cardiovascular Disease Sarasota, FL Medical Doctor

NPI 1336339811 CMS profile 196248

965 S Beneva Rd, Intercoastal Cardiology, Sarasota, FL 34232

Open in the dashboard

General payments

$29,478

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$297,328 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Mark Ramos of Sarasota, FL is reported in the CMS Open Payments database as having received $29,478 across 143 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $297,328 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $775 42
2024 General $3,528 33
2023 General $6,737 40
2022 General $3,324 8
2021 General $134 2
2020 General $2,916 3
2019 General $12,064 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Ramos
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mark Ramos were reported at $775. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mark Ramos Cardiovascular Disease median Middle half National median
2019 $12,064 $450 $127–$1,392 $163
2020 $2,916 $242 $77–$751 $114
2021 $134 $335 $101–$1,037 $132
2022 $3,324 $395 $121–$1,211 $149
2023 $6,737 $443 $136–$1,283 $160
2024 $3,528 $450 $136–$1,323 $164
2025 $775 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $14,743 17 payments
  2. Amgen Inc. $11,668 26 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $598 3 payments
  4. Novartis Pharmaceuticals Corporation $292 18 payments
  5. Merck Sharp & Dohme Corporation $263 13 payments
  6. iRhythm Technologies, Inc. $194 2 payments
  7. Janssen Pharmaceuticals, Inc $179 6 payments
  8. Abbott Laboratories $165 3 payments
  9. Pfizer Inc. $159 9 payments
  10. Biotronik Inc. $152 2 payments
  11. Other $1,067 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,838 10 payments
  2. Food and Beverage $3,687 124 payments
  3. Consulting Fee $1,800 4 payments
  4. Travel and Lodging $636 3 payments
  5. Honoraria $500 1 payment
  6. Education $17 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS $12,924 11 payments
  2. Repatha $11,568 20 payments
  3. LifeVest $598 3 payments
  4. VERQUVO Cardiovascular $297 15 payments
  5. LEQVIO $292 18 payments
  6. XARELTO $179 6 payments
  7. BIOMONITOR $152 2 payments
  8. CARDIOMEMS $141 2 payments
  9. ZIO Patch $120 1 payment
  10. VERQUVO Cardiovascular $114 6 payments
  11. Other $1,566 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

12,187

Median for Cardiology: 2,533

Drug cost

$4,319,772

Median for Cardiology: $485,213

Branded share of claims

34.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,707 $2,180,415
Vyndamax Tafamidis Brand 26 $610,804
Entresto Sacubitril/Valsartan Brand 316 $415,815
Xarelto Rivaroxaban Brand 328 $398,776
Farxiga Dapagliflozin Propanediol Brand 183 $189,965
Repatha Sureclick Evolocumab Brand 164 $173,229
Jardiance Empagliflozin Brand 108 $108,936
Repatha Syringe Evolocumab Brand 61 $49,972
Repatha Pushtronex Evolocumab Brand 33 $28,857
Praluent Pen Alirocumab Brand 21 $15,839

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 115 billing codes

Paid by Medicare

$990,591

Of which drugs: $3,327

Medicare patients

6,930

Average age 78

Services billed

18,248

3,354 women, 3,576 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Ischemic heart disease 53%
Atrial fibrillation 41%
Chronic kidney disease 31%
Diabetes 30%
Heart failure 30%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 123 500 $3,177
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 15 1,410 $151

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $2,369
  • PFIZER INC. $36
$2,406 1,707 —
Repatha
  • Amgen Inc. $105
$105 258 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $58
$58 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $39
$39 328 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record